Multiple Myeloma · line 2 · Ciltacabtagene autoleucel (cilta-cel) BCMA CAR-T for lenalidomide-refractory R/R multiple myeloma after 1-3 prior lines — single infusion after Flu/Cy lymphodepletion (CARTITUDE-4)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-CILTACEL-MM-2L |
| ID | IND-MM-RR-2L-CILTACEL |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | DIS-MM |
| Sources | SRC-CARTITUDE-1-BERDEJA-2021 SRC-ESMO-MM-2023 SRC-NCCN-MM-2025 |
Notes
STUB — requires two clinical co-lead signoffs before publication (CHARTER §6.1). Pivotal trial source CARTITUDE-4 (San-Miguel 2023 NEJM) NOT YET in KB; commit body flags this gap. NCCN-MM-2025 + ESMO-MM-2023 + CARTITUDE-1 (CARTITUDE-4 lineage citation) satisfy Q4 ≥2-source axis pending CARTITUDE-4 ingestion. Distinguishes from IND-MM-RR-3L-CILTACEL by 2L line and lenalidomide-refractory enrolment criterion.
Used By
No reverse references found in the YAML corpus.